Home Intervjuer Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

Cereno granted approval to initiate Phase I trial with CS014

Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

20 juni, 2024

Cereno Scientific is a biotech company developing treatments for the number one killer in the world – cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.

Watch the interview with Cereno‘s CEO Sten R Sörensen below:

YouTube video

Innehållet i BioStocks nyheter och analyser är oberoende men BioStocks verksamhet är i viss mån finansierad av bolag i branschen. Detta inlägg avser ett bolag som BioStock erhållit finansiering från.

Prenumerera på BioStocks nyhetsbrev